Molecule Details
| InChIKey | NGFFVZQXSRKHBM-FKBYEOEOSA-N |
|---|---|
| Canonical SMILES | O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4ccc(C(F)(F)F)cc4[nH]3)ccnc2N1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.67 |
| Source | BindingDB;ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB14773 |
|---|---|
| Drug Name | Lifirafenib |
| CAS Number | 1446090-79-4 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor). |
Categories: Heterocyclic Compounds, Fused-Ring
Cross-references: ChemSpider: 58145118 PDB: 3K3 ZINC: ZINC000068764621
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P15056 | BRAF | Serine/threonine-protein kinase B-raf | inhibitor | targets |